A 24-week course of ganciclovir prophylaxis lowers the risk of cytomegalovirus (CMV) infection in renal transplant recipients

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1541, 2006-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

By McGavin J.K. Goa K.L.

Drugs, Vol. 61, Iss. 8, 2001-01 ,pp. : 1153-1183

Adis International

Access to resources Recommend Favorite

Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

By Noble S. Faulds D.

Drugs, Vol. 56, Iss. 1, 1998-07 ,pp. : 115-146

Adis International

Access to resources Recommend Favorite

Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients

By Bueno J.

Pediatric Drugs, Vol. 4, Iss. 5, 2002-01 ,pp. : 279-290

Adis International

Access to resources Recommend Favorite

Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach

By Gerna Giuseppe Baldanti Fausto Lilleri Daniele

Future Virology, Vol. 4, Iss. 2, 2009-03 ,pp. : 155-164

Future Medicine

Access to resources Recommend Favorite

Strategies for managing cytomegalovirus in transplant recipients

By Razonable Raymund R

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 1983-1997

Informa Healthcare

Access to resources Recommend Favorite